Washington Dc, DCNCT05434234Now EnrollingIRB Ready

Advanced Solid Tumors Clinical Trial in Washington Dc, DC

Access cutting-edge advanced solid tumors treatment through this clinical trial at a research site in Washington Dc. Study-provided care at no cost to qualified participants.

Sponsored by MediLink Therapeutics (Suzhou) Co., Ltd.

Quick Self-Assessment

See if you qualify for this Washington Dc location

Preparing your pre-screening questions...

Expert Care in Washington Dc

Access advanced solid tumors specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related advanced solid tumors treatment provided free

Apply for This Washington Dc Location

Check if you qualify for this advanced solid tumors clinical trial in Washington Dc, DC

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Washington Dc

    Convenient for DC residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Washington Dc site if eligible
  4. 4Begin participation

About This Advanced Solid Tumors Study in Washington Dc

This is a phase 1, multicenter, nonrandomized, open-label, first-in-human study of YL201 conducted in China and the United States. The study will include 2 parts: a dose escalation part (Part 1) followed by a dose expansion part (Part 2). Part 1 will estimate the MTD/RED(s) in dose escalation cohorts of patients with advanced solid tumors unresponsive to currently available therapies or for whom no standard therapy is available. Part 2 will include patients with selected advanced solid tumor t

Sponsor: MediLink Therapeutics (Suzhou) Co., Ltd.

Who Can Participate

Inclusion Criteria

Informed of the trial before the start of the trial and voluntarily sign their name and date on the ICF
Aged ≥18 years
Eastern Cooperative Oncology Group performance status (ECOG PS) of 0 or 1
Adequate organ and bone marrow function
Female patients of childbearing potential must agree to use a highly effective form of contraception and not donate, or retrieve for their own use, ova from the time of screening and throughout the study period, and for at least 5 months after the last dose of atezolizumab or 6 months after the last dose of YL201, whichever is later. Male patients must agree to use a highly effective form of contraception and not freeze or donate sperm from the time of screening and throughout the study period, and for at least 6 months after the last dose of YL201.
Life expectancy of ≥3 months
Able and willing to comply with protocol visits and procedures
Have at least 1 evaluable tumor lesion according to Response Evaluation Criteria i

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Washington Dc?

Yes, this clinical trial (NCT05434234) has an active research site in Washington Dc, DC that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Advanced Solid Tumors Treatment Options in Washington Dc, DC

If you're searching for advanced solid tumors treatment options in Washington Dc, DC, this clinical trial (NCT05434234) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Washington Dc research site is actively enrolling participants for this clinical trial. You'll receive care from experienced advanced solid tumors specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all advanced solid tumors clinical trials near you to find additional studies recruiting in your area.

More Advanced Solid Tumors Trials in Washington Dc, DC

See all advanced solid tumors clinical trials recruiting in Washington Dc — not just this study.

Browse Advanced Solid Tumors Trials in Washington Dc →

Browse More Trials by Condition

Advanced Solid Tumors TrialsAlzheimers Disease TrialsAtopic Dermatitis TrialsErectile Dysfunction TrialsAll Conditions →

Ready to Join in Washington Dc?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Washington Dc, DC